tolvaptan has been researched along with Kidney, Polycystic in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Bhardwaj, G; Dai, DF; Daneshgar, N; Horstmann, MM; Lan, RS; Liang, PI; O'Neill, BT; Pack, L; Penniman, CM | 1 |
| Brownlee, RT; Cleary, HL; Fisher, JL; George, JF; Howton, TC; Lasseigne, BN; McPherson, KC; Mrug, M; Oza, VH; Wilk, EJ; Yoder, BK | 1 |
| Anderson, CL | 1 |
| Goggolidou, P; Malik, SA; Modarage, K; Richards, T | 1 |
| Beau, F; Ciolek, J; De Pauw, E; Droctové, L; Gilles, N; Lombès, M; Mendre, C; Mouillac, B; Mourier, G; Nevoux, J; Orcel, H; Peigneur, S; Quinton, L; Reinfrank, H; Servent, D; Sigismeau, S; Stura, EA; Tytgat, J; Vera, L; Viengchareun, S; Witzgall, R | 1 |
| Czerwiec, FS; Gansevoort, RT; Torres, VE | 1 |
| Le Meur, Y; Wyatt, CM | 1 |
| De Tymowski, C; Legrand, M | 1 |
| Pazmiño, PA | 1 |
| Hirose, T; Ito, S; Kinugasa, S; Mori, T; Muroya, Y; Oba-Yabana, I; Ohsaki, Y; Sato, E; Takahashi, C; Wang, A | 1 |
| Fernández Fresnedo, G; López Del Moral Cuesta, C; Martín Penagos, L | 1 |
| Aihara, M; Fujiki, H; Hattori, K; Ishikawa, M; Mizuguchi, H; Nagano, K; Ohmoto, K; Yamamura, Y | 1 |
| Bellevicine, C; Bisesti, V; Buonocore, P; Cappellaio, F; De Falco, V; Federico, S; Pisani, A; Riccio, E; Russo, L; Sabbatini, M; Troncone, G | 1 |
| Capasso, G; Fiume, I; Pocsfalvi, G; Raj, DA; Trepiccione, F; Vilasi, A | 1 |
| Strutz, F | 1 |
| Bockenhauer, D | 1 |
| Sas, KM | 1 |
| Bichet, DG; Blumenfeld, JD; Coller, B; Mauer, A; Smith, B; Tepler, J | 1 |
| Gattone, V; Harris, PC; Torres, VE; Wang, X | 1 |
| Greenberg, A; Verbalis, JG | 1 |
| Bolignano, D; Buemi, M; Campo, S; Coppolino, G; Criseo, M; Romeo, A | 1 |
| Fujiki, H; Miyazaki, T; Mori, T; Nakamura, S; Yamamura, Y | 1 |
5 review(s) available for tolvaptan and Kidney, Polycystic
| Article | Year |
|---|---|
The cellular pathways and potential therapeutics of Polycystic Kidney Disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Genetic Predisposition to Disease; Humans; Kidney; Mutation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Signal Transduction; Tolvaptan | 2021 |
[Autosomal polycystic kidney disease].
Topics: Antihypertensive Agents; Benzazepines; Diagnostic Imaging; Evidence-Based Medicine; Genetic Testing; Humans; Kidney Function Tests; Polycystic Kidney Diseases; Renal Agents; Tolvaptan; Treatment Outcome | 2016 |
Vasopressin receptor antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Clinical Trials as Topic; Diabetes Insipidus, Nephrogenic; Fibrosis; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Pyrroles; Receptors, Vasopressin; Sodium; Tolvaptan; United States; United States Food and Drug Administration; Vasopressins | 2006 |
Aquaretic agents: what's beyond the treatment of hyponatremia?
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuresis; Diuretics; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Tolvaptan | 2007 |
Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Diuresis; Diuretics; Dogs; Dose-Response Relationship, Drug; Heart Failure; Humans; Hyponatremia; Polycystic Kidney Diseases; Rats; Receptors, Vasopressin; Tolvaptan; Treatment Outcome | 2007 |
17 other study(ies) available for tolvaptan and Kidney, Polycystic
| Article | Year |
|---|---|
Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations.
Topics: Animals; Animals, Newborn; Female; Humans; Male; Mice; Mutation; Oligopeptides; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Pregnancy; Tolvaptan | 2022 |
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.
Topics: Animals; Drug Repositioning; Gene Expression; Humans; Kidney; Mice; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan; TRPP Cation Channels | 2023 |
Doubts about the efficacy of tolvaptan for polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2020 |
Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; Cyclic AMP; Dendroaspis; Female; HEK293 Cells; Humans; Mice; Mice, Inbred C57BL; Natriuretic Peptides; Peptides; Polycystic Kidney Diseases; Receptors, Vasopressin; Signal Transduction; Snake Venoms; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Time Factors; Tolvaptan; Trypsin | 2017 |
Tolvaptan in Later-Stage Polycystic Kidney Disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2018 |
REPRISE: tolvaptan in advanced polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2018 |
Tolvaptan in Later-Stage Polycystic Kidney Disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2018 |
Tolvaptan in Later-Stage Polycystic Kidney Disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2018 |
Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Blood Pressure; Diuretics; Drug Therapy, Combination; Gene Expression; Glomerular Filtration Rate; Hydrochlorothiazide; Male; Nitric Oxide Synthase Type I; Polycystic Kidney Diseases; Polyuria; Prostaglandin-E Synthases; Rats; Renin; RNA, Messenger; Tolvaptan; Urine | 2019 |
Clinical experience with tolvaptan in patients with polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2020 |
Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.
Topics: Acute-Phase Proteins; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Kidney; Kidney Failure, Chronic; Lipocalin-2; Lipocalins; Magnetic Resonance Imaging; Male; Mice; Oncogene Proteins; Organ Size; Polycystic Kidney Diseases; Signal Transduction; Time Factors; Tolvaptan | 2014 |
Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
Topics: Animals; Benzazepines; Cyclic AMP; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Kidney; Male; MAP Kinase Signaling System; Polycystic Kidney Diseases; Rats; Rats, Inbred Strains; Rats, Mutant Strains; Rats, Sprague-Dawley; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Urinary extracellular vesicles as reservoirs of altered proteins during the pathogenesis of polycystic kidney disease.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Biomarkers; Calcium-Binding Proteins; Case-Control Studies; Extracellular Vesicles; Humans; Male; Middle Aged; Polycystic Kidney Diseases; Proteome; Tolvaptan; Wnt Signaling Pathway; Young Adult | 2015 |
Hyponatremia and cyst growth in neonatal polycystic kidney disease: a case for aquaretics?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Infant; Infant, Newborn; Polycystic Kidney Diseases; Receptors, Vasopressin; Tolvaptan | 2017 |
Targeting B-Raf as a treatment strategy for polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Benzenesulfonates; Cell Proliferation; Cells, Cultured; Humans; Niacinamide; Phenylurea Compounds; Polycystic Kidney Diseases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Tolvaptan | 2010 |
Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease.
Topics: Adult; Benzazepines; Blood Coagulation; Blood Coagulation Factors; Deamino Arginine Vasopressin; Down-Regulation; Humans; Male; Polycystic Kidney Diseases; Tolvaptan; von Willebrand Factor | 2011 |
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan | 2005 |